One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis.
about
Management of noninfectious posterior uveitis with intravitreal drug therapyMoving forward in uveitis therapy: preclinical to phase II clinical trial drug development.Unmet Needs and Future Directions in Inflammatory Eye Disease.Sirolimus for the treatment of noninfectious uveitis.The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis).Rapamycin is highly effective in murine models of immune-mediated bone marrow failure.Intravitreal therapeutic agents in noninfectious uveitic macular edema
P2860
Q28074741-366563A8-8543-4D87-A5E1-02DBEA16DF65Q38660708-28317811-CBC3-4CB1-962E-97F04D115C77Q38806044-BD21DFC6-23DC-4DE7-81D8-F2BA3285A8B3Q38938749-DAF05B7E-EF1E-426E-B7DA-8CE6F60B45F1Q40539739-2A4B7C60-CE37-42BD-B9C0-064F22938334Q42368320-79CD8140-DE90-4C6D-8A36-DFF59A1FEDD4Q58806282-E5CAE75F-9E68-48CE-A01C-22724731D963
P2860
One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis.
@en
type
label
One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis.
@en
prefLabel
One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis.
@en
P2093
P2860
P356
P1476
One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis.
@en
P2093
Anthony Watters
Diana V Do
Erin M Vigil
Millena Bittencourt
Mohamed A Ibrahim
Quan Dong Nguyen
Yasir J Sepah
P2860
P356
10.1167/TVST.4.2.4
P577
2015-03-10T00:00:00Z